Human Growth Hormone (Somatropin)
Fat LossFDA-approved recombinant growth hormoneEstablished
FDA-approved recombinant 191-aa human growth hormone for GH deficiency and other labeled indications. WADA prohibits GH at all times (S2).
For research use only.
Key Facts
- CAS
- 12629-01-5
- Molecular Weight (MW)
- 22124 g/mol
- Half-life
- ~3 hours (SC/IM absorption-limited; serum decline ~3–5 hours)
- Unit
- IU
- Administration Route
- Subcutaneous (most common); IM less common
- Frequency
- Typically daily (clinical replacement); varies by indication
- Last updated
- 8/23/2026
- Targets
- Growth hormone receptor
Overview
FDA-approved recombinant 191-aa human growth hormone for GH deficiency and other labeled indications. WADA prohibits GH at all times (S2).
Protocol
- Dosage Range
- Individualized dosing (weight/IGF-1 guided in clinical use)
- Frequency
- Typically daily (clinical replacement); varies by indication
- Cycle
- Use only per FDA labeling / prescriber direction (indication-specific)
- Administration Route
- Subcutaneous (most common); IM less common
- Reconstitution Guide
- Reconstitute only with supplied diluent or bacteriostatic water per product instructions (varies by brand/device)
May vary by vendor concentration and protocol.
Science
Mechanism of Action
Binds GHR to activate JAK2/STAT5, raising IGF-1, increasing lipolysis, and promoting linear growth in deficient children.
Targets
Growth hormone receptor
Studies
- Adult GHD somatropin outcomes— Journal/year not available
Benefits
Labeled GH-deficiency therapyBody-composition effects in GHD
Potential Side Effects
- Edema
- Arthralgia
- Carpal tunnel
- Hyperglycemia
- Intracranial hypertension
References
- FDA somatropin class labeling exampleExternal link · Year —
- WADA Prohibited List 2026External link · Year —